A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for the treatment of participants with second line (2L) esophageal squamous cell carcinoma (ESCC) who have previously been exposed to PD-1/PD-L1 based treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony nowotwór przełyku (rak płaskonabłonkowy) - zaawansowany lub nieoperowalny
- •Choroba pogorszyła się po poprzedniej chemioterapii zawierającej pochodne platyny
- •Wcześniej otrzymywał leczenie immunologiczne anty-PD-1/PD-L1
- •Dostępna próbka tkanki nowotworu do badań
- •Powrócił do zdrowia po skutkach ubocznych poprzedniego leczenia (co najwyżej łagodne objawy)
- •Osoby z cukrzycą lub problemami nerwowymi dobrze kontrolowanymi mogą uczestniczyć
✗ Disqualifies
- •Nowotwór wdarł się do sąsiednich ważnych narządów (aorta, tchawica)
- •Utrata wagi większa niż 10% w ostatnich 2 miesiącach
- •Poważne problemy z oczami (suchość, zapalenie czy zaburzenia gojenia się)
- •Aktywne choroby zapalne jelit wymagające leków immunosupresyjnych
- •Użył eksperymentalnego leku lub urządzenia w ciągu ostatnich 4 tygodni
- •Inny nowotwór aktywny lub leczone w ostatnich 3 latach (poza rakiem skóry)
- •Przerzuty do mózgu lub zapalenie opon mózgowych
- •HIV z historią choroby Kaposiego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (59)
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 4927)
Tucson, United States
UCLA Hematology/Oncology - Santa Monica ( Site 4905)
Los Angeles, United States
Hematology-Oncology Associates of Central NY, P.C. ( Site 4925)
East Syracuse, United States
Columbia University Irving Medical Center-CUIMC Herbert Irving Comprehensive Cancer Center Clinical ( Site 4907)
New York, United States
UPMC Hillman Cancer Center-UPMC ( Site 4904)
Pittsburgh, United States
Liga Norte Riograndense Contra o Câncer ( Site 4303)
Natal, Brazil
Hospital Nossa Senhora da Conceição ( Site 4301)
Porto Alegre, Brazil
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 4300)
São Paulo, Brazil
FALP-UIDO ( Site 4400)
Santiago, Chile
Centro de Oncología de Precisión-Oncology ( Site 4404)
Santiago, Chile
Clínica las Condes ( Site 4403)
Santiago, Chile
Clínica UC San Carlos de Apoquindo ( Site 4405)
Santiago, Chile
Anhui Provincial Hospital ( Site 3501)
Hefei, China
Beijing Cancer hospital-Digestive Oncology ( Site 3500)
Beijing, China
The First Affiliated Hospital of Xiamen University ( Site 3516)
Xiamen, China
The First Affiliated Hospital of Xinxiang Medical University-Oncology ( Site 3510)
Xinxiang, China
Henan Cancer Hospital ( Site 3518)
Zhengzhou, China
First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 3506)
Huai'an, China
Shanghai Chest Hospital-Esophageal surgery department ( Site 3513)
Shanghai, China
Zhejiang Cancer Hospital-Thoracic oncology ( Site 3511)
Hangzhou, China
Institut für Klinisch Onkologische Forschung-Klink für Onkologie und Hämatologie ( Site 4801)
Frankfurt am Main, Germany
Universitaetsklinikum Duesseldorf ( Site 4802)
Düsseldorf, Germany
Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 4806)
Dresden, Germany
Charité Campus Virchow-Klinikum-Klinik Hämatologie Onkologie Tumorimmunologie ( Site 4804)
Berlin, Germany
Facharztzentrum Eppendorf ( Site 4807)
Hamburg, Germany
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 3207)
Meldola, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 3200)
Milan, Italy
Azienda Ospedaliero Universitaria Pisana ( Site 3206)
Pisa, Italy
Istituto Oncologico Veneto IRCCS-Oncologia Medica 1 ( Site 3203)
Padova, Italy
Ospedale San Raffaele-Oncologia Medica ( Site 3202)
Milan, Italy
Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative ( Site 3201)
Milan, Italy
Aichi Cancer Center ( Site 3702)
Nagoya, Japan
National Cancer Center Hospital East ( Site 3701)
Kashiwa, Japan
Saitama Prefectural Cancer Center ( Site 3703)
Kitaadachi-gun, Japan
Shizuoka Cancer Center ( Site 3704)
Nagaizumi-cho,Sunto-gun, Japan
National Cancer Center Hospital ( Site 3700)
Chuo-ku, Japan
Oslo universitetssykehus, Radiumhospitalet ( Site 4501)
Oslo, Norway
National University Hospital ( Site 3800)
Singapore, Singapore
Asan Medical Center-Department of Oncology ( Site 3901)
Seoul, South Korea
Samsung Medical Center-Division of Hematology/Oncology ( Site 3900)
Seoul, South Korea
Hôpitaux Universitaires de Genève (HUG) ( Site 4702)
Geneva, Switzerland
Kantonsspital Graubünden-Medizin ( Site 4700)
Chur, Switzerland
Chang Gung Memorial Hospital at Kaohsiung ( Site 4003)
Kaohsiung Niao Sung Dist, Taiwan
China Medical University Hospital ( Site 4007)
Taichung, Taiwan
Taichung Veterans General Hospital-Radiation Oncology ( Site 4008)
Taichung, Taiwan
National Cheng Kung University Hospital ( Site 4001)
Tainan, Taiwan
National Taiwan University Hospital ( Site 4000)
Taipei, Taiwan
Taipei Veterans General Hospital ( Site 4005)
Taipei, Taiwan
Chang Gung Medical Foundation-Linkou Branch ( Site 4006)
Taoyuan, Taiwan
Faculty of Medicine Siriraj Hospital ( Site 4102)
Bangkoknoi, Thailand
Chulalongkorn University ( Site 4104)
Pathumwan, Thailand
Songklanagarind hospital ( Site 4105)
Hat Yai, Thailand
Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 3417)
Adana, Turkey (Türkiye)
Hacettepe Universite Hastaneleri-oncology hospital ( Site 3402)
Ankara, Turkey (Türkiye)
Memorial Ankara Hastanesi-Medical Oncology ( Site 3408)
Ankara, Turkey (Türkiye)
Ankara Bilkent City Hospital-Medical Oncology ( Site 3405)
Ankara, Turkey (Türkiye)
Atatürk Üniversitesi-onkoloji ( Site 3416)
Erzurum, Turkey (Türkiye)
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 3403)
Istanbul, Turkey (Türkiye)
I.E.U. Medical Point Hastanesi-Oncology ( Site 3406)
Izmir, Turkey (Türkiye)
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.